Procept BioRobotics stock rating reiterated at Buy by TD Cowen

The setup here is less about the new target and more about whether the business is exiting the quarter with its order funnel intact after management changed commercial tactics. If first-quarter procedure growth simply tracks in line, the market can re-rate the name because the prior selloff appears to have priced in a much worse demand inflection than the current operating reality. That creates a classic asymmetry: limited upside to a heroic beat, but meaningful downside if the company needs to cut again.

The real second-order winner is the balance-sheet optionality around international expansion. Early launches outside the U.S. can matter disproportionately for an installed-base platform because even modest overseas utilization helps de-risk the growth curve and improves visibility on future procedure volume; that is especially valuable when domestic sentiment is fragile. Competitively, this is more important for capital equipment peers than for consumable-only medtech names, because any sign of durable adoption can revive hospital budgeting confidence for robotics-adjacent spend.

The main risk is timing. A one-quarter stabilization does not fix the longer-duration issue of whether demand was pulled forward by prior sales behavior, so the stock could still fade if the April print is merely good enough rather than truly reaccelerating. The contrarian view is that consensus may be underestimating how quickly sentiment can normalize if management stops leaning on quarter-end tactics and simply demonstrates clean execution; in this setup, narrative repair can drive the next 10-15% move faster than fundamentals alone would imply.